Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .
Record details
Published: 4 August 2026
Source: MedCity News AI
Category: News
Topics: Healthcare · Agents & autonomy · Biotech
Retrieved: 5 August 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
Startup to Acquisition in 2 Years: Grove AI’s Journey to Transform Clinical Trials
MedCity News AI · 31 July 2026
The path to artificial superintelligence
MIT Technology Review · 27 July 2026
The world’s largest ‘biological datacenter’ could help make animal testing obsolete
Fast Company Tech · 13 August 2026
STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
STAT News (health AI, headlines) · 29 June 2026
The Clinical Trial Pipeline Reveals the Next Wave of Artificial Intelligence in Healthcare: A Multidimensional Analysis of 8,532 Registered Studies
arXiv cs.CY · 28 July 2026
Do AI-Native Biotechs Need Departments? Benchmarking Company World Models for AI-Driven Drug Development
arXiv · 21 July 2026
How to cite this record
ethics.ai (4 August 2026), “Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents,” evidence record 16431, https://ethics.ai/record/16431 (originally published by MedCity News AI).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.